Tag: fiscal year

VERO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of June 2026. The dividend of $0.10 per share will be paid July 30, 2026 to holders of record of the Company’s common stock on June 30, 2026, with an ex-dividend date of June 30, 2026. The Company plans on announcing its next common stock dividend on July 8, 2026.

Paul Miller Rejoins Grocery Outlet as Chief Purchasing and Merchandising Officer
Ian Ferry Promoted to Chief Financial Officer
Company Affirms Second Quarter and Fiscal 2026 Outlook

Net sales increased 22.5% year-over-year to $107.1 million

UBISOFT ENTERTAINMENT S.A.

Royal Uranium Approval Expected to Advance Company's Potential Transformation into a Diversified Energy Platform

GUANGZHOU, China, June 09, 2026 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading advanced air mobility (“AAM”) technology platform company, today announced its unaudited financial results for the first quarter ended March 31, 2026.

NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Cipher Digital Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) a leading developer, owner, and operator of industrial-scale data centers, today announced that its wholly-owned subsidiary, Stingray Compute LLC (the “Issuer”), has priced a $810.0 million offering of 6.000% senior secured notes due 2031 (the “Notes”) at a price equal to 99.750% of their principal amount. The Notes will be sold in a private offering to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside of the United States pursuant to Regulation S under the Securities Act. The offering is expected to close on June 15, 2026, subject to customary closing conditions.

Acquisition of Calavo Growers completed May 28, 2026

Reports Full-Year Revenue of $70 Million and Adjusted EBITDA of $8.3 Million, Exceeding Increased Adjusted EBITDA Guidance Range; Fourth Consecutive Quarter of Positive Operating Cash Flow

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas